The closing price of Kezar Life Sciences Inc (NASDAQ: KZR) was $0.89 for the day, down -2.31% from the previous closing price of $0.92. In other words, the price has decreased by -$0.0211 from its previous closing price. On the day, 1391703 shares were traded.
Ratios:
Our analysis of KZR’s different ratios will help us gain a deeper understanding of the company. For the most recent quarter (mrq), Quick Ratio is recorded 11.66 and its Current Ratio is at 11.66. In the meantime, Its Debt-to-Equity ratio is 0.10 whereas as Long-Term Debt/Eq ratio is at 0.08.
On December 08, 2021, Wells Fargo started tracking the stock assigning a Overweight rating and target price of $19.Wells Fargo initiated its Overweight rating on December 08, 2021, with a $19 target price.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, KZR now has a Market Capitalization of 65.66M and an Enterprise Value of -116.78M. For the stock, the TTM Price-to-Sale (P/S) ratio is 9.30 while its Price-to-Book (P/B) ratio in mrq is 0.35. Its current Enterprise Value per Revenue stands at -16.68 whereas that against EBITDA is 1.18.
Stock Price History:
The Beta on a monthly basis for KZR is 0.48, which has changed by -72.45% over the last 52 weeks, in comparison to a change of 29.19% over the same period for the S&P500. Over the past 52 weeks, KZR has reached a high of $3.66, while it has fallen to a 52-week low of $0.67. The 50-Day Moving Average of the stock is 0.9110, while the 200-Day Moving Average is calculated to be 1.2885.
Shares Statistics:
KZR traded an average of 675.18K shares per day over the past three months and 948.25k shares per day over the past ten days. A total of 72.78M shares are outstanding, with a floating share count of 61.87M. Insiders hold about 15.01% of the company’s shares, while institutions hold 65.11% stake in the company. Shares short for KZR as of Feb 29, 2024 were 3.18M with a Short Ratio of 4.71, compared to 3.05M on Jan 31, 2024. Therefore, it implies a Short% of Shares Outstanding of 4.37% and a Short% of Float of 4.52%.
Earnings Estimates
The firm’s stock currently is rated by 5 analysts. On average, analysts expect EPS of -$0.35 for the current quarter, with a high estimate of -$0.3 and a low estimate of -$0.41, while EPS last year was -$0.31. The consensus estimate for the next quarter is -$0.34, with high estimates of -$0.26 and low estimates of -$0.45.
Analysts are recommending an EPS of between -$1.02 and -$1.83 for the fiscal current year, implying an average EPS of -$1.37. EPS for the following year is -$1.22, with 5 analysts recommending between -$0.85 and -$1.55.
